Clinical Trial Update: Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. [Phase 4]

View source ↗

Summary

Phase 4 investigation evaluating changes in vision-related quality of life in subjects with macular edema treated with aflibercept according to EU label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Macular Edema | Phase 4 | Status: COMPLETED | Results posted: 2018-10-10